Civil Money Penalties Relating to the ClinicalTrials.gov Data Bank: Guidance for Responsible Parties, Submitters of Certain Applications and Submissions to FDA, and FDA Staff

Information

Type

Guidance

Regulated products

Biologics, Drugs, Medical Devices

Topics

Good Clinical Practice (GCP)

Published

August 14, 2020

Last updated

August 14, 2020

Description

This document provides guidance on civil money penalties related to ClinicalTrials.gov data bank for responsible parties, submitters, and FDA staff.

Organization

Country / Region

United States

License

Other (Public Domain)

Feedback

Suggest an improvement to this page

Actions

Social networks

Embed